A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Inapsine Pharmacology, Pharmacokinetics, Studies, Metabolism - Droperidol
Inapsine Pharmacology, Pharmacokinetics, Studies, Metabolism - Droperidol
CLINICAL PHARMACOLOGY
INAPSINE (droperidol) produces marked tranquilization and sedation.
It allays apprehension and provides a state
of mental detachment
and indifference while maintaining a state
of reflex alertness.
INAPSINE produces an antiemetic
effect as evidenced by
the antagonism of apomorphine
in dogs. It lowers the incidence
of nausea and vomiting
during surgical procedures
and provides antiemetic
protection in the postoperative period. INAPSINE potentiates other
CNS depressants. It produces
mild alpha-adrenergic blockade, peripheral
vascular dilatation
and reduction of the
pressor effect of epinephrine.
It can produce hypotension
and decreased peripheral
vascular resistance and may decrease pulmonary
arterial pressure
(particularly if it is abnormally high). It may reduce
the incidence of epinephrine-induced
arrhythmias, but it does not prevent other cardiac
arrhythmias. The onset of action
of single intramuscular
and intravenous
doses is from three to ten minutes following administration, although
the peak effect may not
he apparent for up
to thirty minutes. The duration
of the tranquilizing and sedative
effects generally is two to four hours, although alteration of alertness
may persist for as long as twelve hours.
top
